Blockade of the PD-L1/PD1 axis prevents inhibition of T-cell function, while blockade of CTLA-4 induces expansion of tumor reactive T-cells [4, 5] and there is strong interest in identifying small-molecule-immunotherapy combinations to increase the proportion of responses to checkpoint blockade. Here, PDCD1 is linked to neoplasm.